Sign Out
Applies only to single presentation forms: FOLISAN (r-hFSH) must not be administered as a mixture with other medicinal products in the same injection, except lutropin alfa or combination of lutropin alfa and follitropin alfa for which studies have shown that co-administration does not significantly alter the activity, stability, pharmacokinetics nor pharmacodynamic properties of the active substances.
Applies to all presentation forms: Concomitant use of FOLISAN (r-hFSH) with other medicinal products used to stimulate ovulation (e.g. HCG, clomiphene citrate) may potentiate the follicular response, whereas concurrent use of a GnRH agonist or antagonist to induce pituitary desensitisation may increase the dose of FOLISAN (r-hFSH) needed to elicit an adequate ovarian response. No other clinically significant medicinal product interaction has been reported during FOLISAN (r-hFSH) therapy.
